Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma.

Andrzej BozekBarbara RogalaMartyna MiodonskaGiorgio Walter Canonica

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2023)

The combination of HDM SCIT and omalizumab is significantly and progressively reducing ICS use and AX in a 24-month study. The combination is significantly more effective than the single treatments or placebo.

Keyphrases

multiple sclerosis
chronic obstructive pulmonary disease
allergic rhinitis
cystic fibrosis
double blind
phase iii